This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ICAD Reports First Quarter Financial Results

iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported financial results for the three months ended March 31, 2014.

“The first quarter of 2014 represented our seventh consecutive quarter of year-over-year revenue growth and positive adjusted EBITDA, driven by a 32% increase in Therapy revenues. In addition, we are pleased to report that recurring service and supply revenue from Therapy and Cancer Detection grew 39% compared with the same period in 2013. These results provide a solid revenue foundation for future quarters,” said Ken Ferry, President and CEO of iCAD.

“Recurring service and supply revenue in our Therapy business nearly doubled compared with the year-ago quarter and underscores an expanding customer base and higher procedure volume, especially for the treatment of non-melanoma skin cancer. In addition, we believe that the growing body of clinical evidence will drive more widespread adoption of Xoft electronic brachytherapy for the treatment of non-melanoma skin cancers and certain breast cancers. We are very early in the adoption curve with the Xoft system and believe that our investments in clinical studies, education and awareness of the clinical benefits will accelerate growth throughout 2014 and beyond.

“During the first quarter, we significantly strengthened our balance sheet with an underwritten public offering of common stock that raised approximately $28.2 million after expenses. Over time, we plan to focus our investments to further accelerate adoption in both the Therapy and Cancer Detection businesses,” added Mr. Ferry.

First Quarter Financial Results

Revenue: Total revenue for the first quarter of 2014 increased 7.4% to $8.5 million from $7.9 million for the first quarter of 2013, reflecting a 32% increase in Therapy revenue partially offset by a 10% decline in Cancer Detection revenue.

Therapy revenue included Xoft® Axxent® Electronic Brachytherapy System® product sales, as well as the associated service and supply revenue. Cancer Detection revenue included film, digital mammography, MRI and CT CAD platforms, as well as service and supply revenue from these products.
Three months ended March 31,

  2014     2013   % Change  
Products $ 2,145   $ 2,161   (0.7 %)
Service and supply   2,200     1,131  

Total revenue $ 4,345   $ 3,292   32.0 %

Three months ended March 31,

Cancer Detection
  2014     2013   % Change  
Products $ 2,064 $ 2,673 (22.8 )%
Service and supply   2,111     1,965   7.4 %
Total revenue $ 4,175   $ 4,638   (10.0 )%

Gross Profit: Gross profit for the first quarter of 2014 increased to $5.9 million, or 69.6% of revenue, from $5.6 million, or 71.2% of revenue, for the first quarter of 2013. The lower gross profit percentage was primarily due to higher Therapy revenue that currently has a lower gross profit percentage.

Operating Expenses: Total operating expenses for the first quarter of 2014 increased to $6.4 million from $6.0 million for the same period in 2013, as a result of higher sales, marketing and R&D expenditures.

Non-GAAP Adjusted EBITDA: Non-GAAP adjusted EBITDA, a non-GAAP financial measure as defined below, was $447,000 for the first quarter of 2014, compared with non-GAAP adjusted EBITDA of $592,000 for the same period in 2013.

Net Loss: The net loss for the first quarter of 2014 was $190,000, or $0.02 per share, compared with a net loss for the first quarter of 2013 of $727,000, or $0.07 per share.

Non-GAAP Adjusted Net Loss: The non-GAAP adjusted net loss, as defined below, for the first quarter of 2013 was $1.3 million, or $0.12 per share, compared with a non-GAAP adjusted net loss for the first quarter of 2012 of $1.2 million, or $0.11 per share.

Cash and Cash Flow: As of March 31, 2014, iCAD had cash and cash equivalents of $38.4 million, compared with $11.9 million as of December 31, 2013. In March 2014, the Company completed an underwritten public offering of 2.76 million common shares at a price of $11.00 per share. Net proceeds from the offering were approximately $28.2 million, after deducting underwriting discounts and offering expenses. Net cash used by operations during first quarter of 2014 was $1.7 million.

Use of Non-GAAP Financial Measures

In its quarterly news releases, conference calls, slide presentations or webcasts, the Company may use or discuss non-GAAP financial measures as defined by SEC Regulation G. The GAAP financial measures most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between each non-GAAP financial measure and the comparable GAAP financial measure, are included in this press release after the condensed consolidated financial statements. When analyzing the Company's operating performance, investors should not consider these non-GAAP measures as a substitute for the comparable financial measures prepared in accordance with GAAP. The Company's quarterly news releases containing such non-GAAP reconciliations can be found on the Investors section of the Company's website at

Conference Call

iCAD management will host an investment community conference call today beginning at 5:00 p.m. Eastern time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 888-713-4211 (domestic) or 617-213-4864 (international) and entering passcode 18462844. The call also will be broadcast live on the Internet at and

A replay of the conference call will be accessible two hours after its completion through May 8, 2014 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering passcode 96441598. The call will also be archived for 90 days at and

About iCAD, Inc.

iCAD is an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. iCAD offers a comprehensive range of high-performance, upgradeable CAD solutions for mammography and advanced image analysis and workflow solutions for Magnetic Resonance Imaging, for breast and prostate cancers and Computed Tomography for colorectal cancer. iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System®, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. The Xoft System is also cleared for the treatment of non-melanoma skin cancer and gynecological cancers. For more information, call 877-iCADnow, or visit

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at and on the SEC’s website at
Condensed Consolidated Balance Sheets
(In thousands except for share data)
March 31,   December 31,



Current assets:
Cash and cash equivalents $ 38,395 $ 11,880

Trade accounts receivable, net of allowance for doubtful accounts of $63 in 2014 and $73 in 2013
7,548 7,623
Inventory, net 1,965 1,891
Prepaid expenses and other current assets 639   649  
Total current assets 48,547   22,043  

Property and equipment, net of accumulated depreciation and amortization of $3,819 in 2014 and $4,265 in 2013
1,664 1,671
Other assets 350 419

Intangible assets, net of accumulated amortization of $12,841 in 2014 and $12,468 in 2013
13,316 13,674
Goodwill 21,109   21,109  
Total assets $ 84,986   $ 58,916  

Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable $ 1,201 $ 2,000
Accrued and other expenses 3,365 3,799
Interest payable 578 483
Notes and lease payable - current portion 3,882 3,878
Warrant liability 2,850 3,986
Deferred revenue 8,403   8,306  
Total current liabilities 20,279   22,452  
Deferred revenue, long-term portion 1,509 1,726
Other long-term liabilities 1,154 1,356
Capital lease - long-term portion 198 235
Notes payable - long-term portion 11,905   11,770  
Total liabilities 35,045   37,539  
Stockholders' equity:

Preferred stock, $ .01 par value: authorized 1,000,000 shares; none issued.
- -

Common stock, $ .01 par value: authorized 85,000,000 shares; issued 13,958,183 in 2014 and 11,084,119 in 2013; outstanding 13,772,352 in 2014 and 10,898,288 in 2013
140 111
Additional paid-in capital 195,460 166,735
Accumulated deficit (144,244 ) (144,054 )
Treasury stock at cost, 185,831 shares in 2013 and 2012 (1,415 ) (1,415 )
Total stockholders' equity 49,941   21,377  
Total liabilities and stockholders' equity $ 84,986   $ 58,916  
Condensed Consolidated Statements of Operations
(In thousands except for per share data)
Three Months Ended March 31,
  2014     2013  
Products $ 4,209 $ 4,834
Service and supplies 4,311   3,096  
Total revenue 8,520 7,930
Cost of revenue:
Products 1,199 1,162
Service and supplies 1,146 887
Amortization of acquired intangibles 241   233  
Total cost of revenue 2,586 2,282
Gross profit 5,934   5,648  
Operating expenses:
Engineering and product development 2,027 1,866
Marketing and sales 2,619 2,438
General and administrative 1,748   1,672  
Total operating expenses 6,394 5,976
Loss from operations (460 ) (328 )
Gain from change in fair value of warrant 1,136 431
Interest expense (817 ) (826 )
Other income 4   6  
Other income (expense), net 323 (389 )
Loss before income tax expense (137 ) (717 )
Tax expense (53 ) (10 )
Net loss and comprehensive loss $ (190 ) $ (727 )
Net loss per share:
Basic and diluted $ (0.02 ) $ (0.07 )

Weighted average number of shares used in computing loss per share:
Basic and diluted 11,429   10,820  
Condensed Consolidated Statements of Cash Flows
  For the three months ended March 31,
2014     2013  
(in thousands)
Cash flow from operating activities:
Net loss $ (190 ) $ (727 )

Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation 209 183
Amortization 373 430
Bad debt expense (benefit) (14 ) 35
Gain from change in fair value of warrant (1,136 ) (431 )
Loss on disposal of assets - 25
Stock-based compensation expense 325 307
Amortization of debt discount and debt costs 183 198
Interest on settlement obligations 52 75
Changes in operating assets and liabilities:
Accounts receivable 88 (521 )
Inventory (74 ) 346
Prepaid and other current assets 30 (63 )
Accounts payable (799 ) (215 )
Accrued expenses (593 ) (1,403 )
Deferred revenue (119 ) 592  
Total adjustments (1,475 ) (442 )
Net cash used for operating activities (1,665 ) (1,169 )
Cash flow from investing activities:
Additions to patents, technology and other (15 ) (2 )
Additions to property and equipment (202 ) (97 )
Net cash used for investing activities (217 ) (99 )
Cash flow from financing activities:
Issuance of common stock for cash 28,243 -
Stock option exercises 287 -
Taxes paid related to restricted stock issuance (101 ) (7 )
Payments of capital lease obligations (32 ) -  
Net cash (used for) provided by financing activities 28,397   (7 )
Increase (decrease) in cash and equivalents 26,515 (1,275 )
Cash and equivalents, beginning of period 11,880   13,948  
Cash and equivalents, end of period $ 38,395   $ 12,673  


The following is a reconciliation of the non-GAAP financial measures used by the Company to describe the Company's financial results determined in accordance with United States generally accepted accounting principles (GAAP). An explanation of these measures is also included below under the heading "Explanation of Non-GAAP Financial Measures."

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.99 0.00%
FB $102.01 0.00%
GOOG $682.40 0.00%
TSLA $151.04 0.00%
YHOO $27.04 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs